Aloxi gains indication

The FDA has approved Aloxi (palonosetron hydrochloride injection, from Eisai and Helsinn Healthcare) for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Aloxi is already indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and for the prevention of acute nausea and vomiting associated with initial and repeat course of highly emetogenic chemotherapy.

For more information call (800) 562-5580 or visit www.aloxi.com.